Why the study?
Is oral and low dose intravenous prostaglandin E2 effective and safe for the management of ductus dependent congenital heart disease in infants?
Is oral and low dose intravenous prostaglandin E2 effective and safe for the management of ductus dependent congenital heart disease in infants?
Oral and low-dose intravenous prostaglandin E2 is an effective and well-tolerated strategy for maintaining ductal patency in infants with ductus dependent congenital heart disease prior to surgery.
Answers are grounded in this paper and cite their sources.
May support oral PGE2 as bridge to surgery in duct-dependent CHD; leaves open need for prospective trials to confirm safety.
Prostaglandin E2 was given orally to 59 infants with ductus dependent congenital heart disease, and intravenous infusions were substituted for varying periods in 27 of them. An additional three neonates received intravenous treatment alone. Mean oral maintenance dose was 27 micrograms/kg per hour and the mean intravenous dose was 0.005 micrograms/kg per minute. Mean duration of treatment was 49 days (range 16 hours to 272 days). Oral treatment was almost always effective and was especially suitable for long term use. Low dose intravenous treatment was readily substituted when indicated. Complications were usually 'minor'. Growth of the infants and of their pulmonary arteries facilitated later surgical management.
No takes yet. Share an insight, caveat, or question.
Silove et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: